Targeted Oncology
Scope & Guideline
Connecting breakthroughs with clinical applications.
Introduction
Aims and Scopes
- Targeted Therapies in Oncology:
The journal emphasizes the development and application of targeted therapies, including small molecules, monoclonal antibodies, and antibody-drug conjugates, for various malignancies. - Molecular Characterization of Tumors:
Research focusing on the molecular and genetic profiling of tumors to identify actionable mutations and guide treatment decisions is a key area of focus. - Real-World Evidence and Outcomes:
Targeted Oncology publishes studies that provide insights into real-world treatment patterns, patient outcomes, and the effectiveness of therapies in diverse populations. - Clinical Trials and Drug Development:
The journal includes reports on clinical trials, particularly phase 1 and 2 studies that assess the safety and efficacy of new agents, as well as combination therapies. - Immunotherapy and Combination Approaches:
Research examining the intersection of immunotherapy with targeted therapies, including immune checkpoint inhibitors and their role in enhancing treatment outcomes. - Emerging Biomarkers and Predictive Models:
Studies identifying new biomarkers that predict responses to therapy and the development of prognostic models are central to the journal's aims.
Trending and Emerging
- Integrative Approaches to Precision Medicine:
There is a growing trend toward integrating genomic, transcriptomic, and proteomic data to develop personalized treatment strategies tailored to individual patients. - Real-World Evidence Studies:
An increase in real-world evidence studies showcasing treatment effectiveness, patient adherence, and outcomes in routine clinical practice reflects the journal's focus on practical applications of research. - Biomarker-Driven Therapy:
Emerging research centers on identifying and validating biomarkers that guide therapy selection, particularly in the context of targeted and immunotherapies. - Combination Therapies:
The exploration of combination therapies that leverage both targeted and immunotherapeutic agents is gaining prominence, underscoring the complexity of cancer treatment. - Patient-Centric Research:
There is an increased focus on patient-reported outcomes, quality of life studies, and the psychosocial aspects of cancer treatment, reflecting a holistic approach to oncology.
Declining or Waning
- Traditional Chemotherapy:
There is a noticeable decline in publications centered around traditional chemotherapy regimens as the focus shifts toward targeted therapies and immunotherapy. - Single-Agent Studies:
Research exclusively investigating the efficacy of single-agent therapies is less prevalent as combination therapies gain more traction in clinical settings. - General Cancer Epidemiology:
While still important, broad epidemiological studies without a targeted focus on molecular mechanisms or specific therapies have become less emphasized. - Non-Molecularly Targeted Treatment Strategies:
The emphasis on non-targeted treatment strategies is decreasing as precision medicine and personalized therapy approaches dominate the landscape. - Basic Science without Clinical Relevance:
Studies that do not bridge laboratory research with clinical implications are less frequently published, as there is a stronger push for translational research.
Similar Journals
Clinical Genitourinary Cancer
Empowering professionals with cutting-edge findings.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
JTO Clinical and Research Reports
Pioneering Excellence in Clinical and Research InsightsJTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.
MOLECULAR CANCER THERAPEUTICS
Transforming cancer care with cutting-edge research.MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Fostering knowledge and collaboration in oncology.The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.
Journal of Bone Oncology
Bridging Science and Practice in Bone Cancer CareJournal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.
Clinical Lung Cancer
Innovative insights for the future of pulmonary medicine.Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.
Leukemia Research Reports
Connecting researchers to combat leukemia.Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.
npj Precision Oncology
Shaping Tomorrow's Cancer Treatments Todaynpj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.
Surgical Oncology Clinics of North America
Elevating Surgical Oncology Standards, One Article at a TimeSurgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.
World Journal of Clinical Oncology
Empowering Oncology with Cutting-Edge InsightsWorld Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.